<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Gender differences in both vulnerability to <z:hpo ids='HP_0001297'>stroke</z:hpo> and outcome following <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> have frequently been observed and attributed to the action of steroid hormones </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="28" ids="17026">Progesterone</z:chebi> is a candidate neuroprotective factor for <z:hpo ids='HP_0001297'>stroke</z:hpo>; however, studies are lacking which: (i) study those groups representing high risk i.e. postmenopausal females; (ii) administer <z:chebi fb="28" ids="17026">progesterone</z:chebi> solely post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>; and (iii) combine histopathological and functional assessments </plain></SENT>
<SENT sid="2" pm="."><plain>Postmenopausal females, along with males, represent the group at highest risk of cerebral <z:hpo ids='HP_0001297'>stroke</z:hpo> and can be modelled using aged or ovariectomized animals </plain></SENT>
<SENT sid="3" pm="."><plain>In the current study, we aimed to determine the neuroprotective effects of <z:chebi fb="28" ids="17026">progesterone</z:chebi> administration following <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in aged and ovariectomized mice </plain></SENT>
<SENT sid="4" pm="."><plain>Following transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, <z:chebi fb="28" ids="17026">progesterone</z:chebi> was administered at 1, 6 and 24 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> to aged and ovariectomized female mice </plain></SENT>
<SENT sid="5" pm="."><plain>At 48 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, <z:chebi fb="28" ids="17026">progesterone</z:chebi> significantly reduced the lesion volume (P &lt; 0.05) but had no effect on neurological outcome in aged female mice </plain></SENT>
<SENT sid="6" pm="."><plain>Whereas in ovariectomized mice, at 48 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, <z:chebi fb="28" ids="17026">progesterone</z:chebi> treatment had no effect on the amount of lesion volume present but did significantly improve neurological outcome </plain></SENT>
<SENT sid="7" pm="."><plain>In a further study of ovariectomized mice, allowed to survive for 7 days post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, <z:chebi fb="28" ids="17026">progesterone</z:chebi> treatment significantly improved motor outcome as assessed using both the rotarod and grid test </plain></SENT>
<SENT sid="8" pm="."><plain>In fact, by 7 days post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, <z:chebi fb="28" ids="17026">progesterone</z:chebi>-treated ovariectomized mice did not differ significantly in performance compared with shams, whereas vehicle-treated ovariectomized mice displayed a significant functional impairment following <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The current study has demonstrated that <z:chebi fb="28" ids="17026">progesterone</z:chebi> has different neuroprotective effects whether it is administered to aged or ovariectomized female mice and emphasizes the need to combine histopathological and functional outcomes within the same study </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, as <z:chebi fb="28" ids="17026">progesterone</z:chebi>-only treatment may not improve <z:hpo ids='HP_0000001'>all</z:hpo> outcomes in <z:hpo ids='HP_0000001'>all</z:hpo> groups, therapies that combine <z:chebi fb="28" ids="17026">progesterone</z:chebi> with other neuroprotective candidates should be investigated to maximize benefit following <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>